hVIVO Past Earnings Performance
Past criteria checks 6/6
hVIVO has been growing earnings at an average annual rate of 77.9%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 37.7% per year. hVIVO's return on equity is 45.4%, and it has net margins of 26%.
Key information
77.9%
Earnings growth rate
86.0%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 37.7% |
| Return on equity | 45.4% |
| Net Margin | 26.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How hVIVO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 67 | 17 | 0 | 0 |
| 31 Mar 24 | 63 | 17 | 0 | 0 |
| 31 Dec 23 | 59 | 16 | 0 | 0 |
| 30 Sep 23 | 60 | 9 | 0 | 0 |
| 30 Jun 23 | 60 | 3 | 0 | 0 |
| 31 Mar 23 | 56 | 1 | 0 | 0 |
| 31 Dec 22 | 51 | -1 | 0 | 0 |
| 30 Sep 22 | 43 | -1 | 0 | 0 |
| 30 Jun 22 | 35 | -1 | 0 | 0 |
| 31 Mar 22 | 37 | -1 | 0 | 0 |
| 31 Dec 21 | 39 | 0 | 0 | 0 |
| 30 Sep 21 | 39 | -2 | 1 | 0 |
| 30 Jun 21 | 39 | -3 | 1 | 0 |
| 31 Mar 21 | 30 | -7 | 1 | 0 |
| 31 Dec 20 | 22 | -11 | 2 | 0 |
| 30 Sep 20 | 16 | -11 | 1 | 0 |
| 30 Jun 20 | 10 | -11 | 1 | 0 |
| 31 Mar 20 | 7 | -8 | 0 | 0 |
| 31 Dec 19 | 3 | -6 | 0 | 0 |
| 30 Jun 19 | 0 | -2 | 0 | 0 |
| 31 Mar 19 | 0 | -1 | 0 | 0 |
Quality Earnings: CRO has high quality earnings.
Growing Profit Margin: CRO's current net profit margins (26%) are higher than last year (4.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRO has become profitable over the past 5 years, growing earnings by 77.9% per year.
Accelerating Growth: CRO's earnings growth over the past year (506.8%) exceeds its 5-year average (77.9% per year).
Earnings vs Industry: CRO earnings growth over the past year (506.8%) exceeded the Life Sciences industry 5.4%.
Return on Equity
High ROE: CRO's Return on Equity (45.4%) is considered outstanding.